PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34863046-3	2022	BCAA plasma levels (isoleucine, leucine and valine) were measured at fasting and after 120 min of an oral glucose tolerance test (OGTT) at the baseline of the study and after 5 y of the dietary intervention.	Isoleucine	20-30	AT-rich interaction domain 4B	Homo sapiens	0-4	
34603012-6	2021	Mapping of BCAA metabolism was performed using mass spectrometry and enriched (15N) and (13C) isotopes of leucine, isoleucine, and valine in acutely isolated slices of surgically resected cerebral cortical tissue from human brain and in hiPSC-derived brain cells carrying mutations in either amyloid precursor protein (APP) or presenilin-1 (PSEN-1).	Isoleucine	115-125	AT-rich interaction domain 4B	Homo sapiens	11-15	
2467054-4	1989	Increased concentrations of aromatic amino acids: phenylalanine and tyrosine, and low concentrations of branched-chain amino acids: valine, leucine, and isoleucine were associated with a decrease of Fisher"s index (BCAA/AAA molar ratio) from 3.0 +/- 0.5 (normal) to 2.0 +/- 0.5 which was of high diagnostic and prognostic significance.	Isoleucine	153-163	AT-rich interaction domain 4B	Homo sapiens	215-219	
35299066-1	2022	This review provides insight into the effects of the branched-chain amino acids (BCAA: leucine, isoleucine, and valine) on the growth, production performance, immunity, and intestinal health of poultry.	Isoleucine	96-106	AT-rich interaction domain 4B	Homo sapiens	81-85	
2772920-2	1989	Three branched chain amino acids (BCAA: valine + leucine + isoleucine) were decreased in all three diseases in comparison with controls.	Isoleucine	59-69	AT-rich interaction domain 4B	Homo sapiens	34-38	
30563270-10	2018	Nevertheless, our data suggest that only an increase in total BCAA, also richer in single AA leucine, isoleucine, and methionine, is associated with the maintenance and/or increase of SMM.	Isoleucine	102-112	AT-rich interaction domain 4B	Homo sapiens	62-66	
3563885-5	1987	Patients receiving the 45% BCAA solution had significant mean uptake of total BCAA, leucine, and isoleucine compared with results in patients receiving the 25% BCAA solution.	Isoleucine	97-107	AT-rich interaction domain 4B	Homo sapiens	27-31	
6433495-7	1984	Plasma leucine, isoleucine and valine concentrations were also significantly increased with administration of the BCAA enriched solution, whereas plasma levels of glycine, tyrosine and phenylalanine were significantly reduced.	Isoleucine	16-26	AT-rich interaction domain 4B	Homo sapiens	114-118	
30734935-7	2019	Plasma levels were particularly low in patients who received amino acid mixtures (AAMs-OAD) and L-isoleucine:L-leucine:L-valine (BCAA) ratio was 1.0:3.0:3.2.	Isoleucine	96-108	AT-rich interaction domain 4B	Homo sapiens	129-133	
33023275-1	2020	Leucine, isoleucine and valine (i.e., the branched chain amino acids, BCAA) play a key role in the support and regulation of tissue protein regulation and also as energy substrates.	Isoleucine	9-19	AT-rich interaction domain 4B	Homo sapiens	70-74	
32960988-1	2021	BACKGROUND: Branched-chain amino acids (BCAA: leucine, isoleucine, and valine) are essential amino acids involved in biological functions of brain development and recently linked with autism.	Isoleucine	55-65	AT-rich interaction domain 4B	Homo sapiens	40-44	
30063118-1	2018	Branched-chain amino acids (BCAA: leucine, isoleucine and valine) are essential amino acids implicated in glucose metabolism and maintenance of correct brain function.	Isoleucine	43-53	AT-rich interaction domain 4B	Homo sapiens	28-32	
24178641-2	1996	The method allows quantitation of the branched chain amino acids (BCAA"s) such as leucine, isoleucine and valine and of related keto- and hydroxy acids by means of a single spectrum.	Isoleucine	91-101	AT-rich interaction domain 4B	Homo sapiens	66-70	
22189890-1	2012	Changes in plasma aromatic amino acids (AAA = phenylalanine, tryptophan, tyrosine) and branched chain amino acids (BCAA = isoleucine, leucine, valine) levels possibly influencing intracranial pressure (ICP) and cerebral oxygen consumption (SjvO(2)) were investigated in 19 sedated patients up to 14 days following severe traumatic brain injury (TBI).	Isoleucine	122-132	AT-rich interaction domain 4B	Homo sapiens	115-119	
14684173-1	2004	Branched-chain amino acid (BCAA: Leu, Ile, and Val) mixture has been used for treatment of hypoalbuminemia in patients with decompensated liver cirrhosis in Japan.	Isoleucine	38-41	AT-rich interaction domain 4B	Homo sapiens	27-31	
25674427-8	2014	The rate of decline among peak plasma BCAA concentrations was the highest for leucine, followed by isoleucine and valine.	Isoleucine	99-109	AT-rich interaction domain 4B	Homo sapiens	38-42	
23560894-3	2013	Because catabolism of branched-chain amino acids (BCAAs; i.e., valine, isoleucine, and leucine) leads to glucose and energy metabolism, and neurotransmitter synthesis and availability, we investigated BCAA metabolites in plasma samples collected within 24 h of injury from mild TBI (Glasgow Coma Scale [GCS] score >12), severe TBI (GCS <=8), orthopedic injury, and healthy volunteers.	Isoleucine	71-81	AT-rich interaction domain 4B	Homo sapiens	50-54	
21169225-1	2011	Beneficial effects on body weight of supplementation with BCAA, including leucine, isoleucine, and valine, have been observed in animal and human studies.	Isoleucine	83-93	AT-rich interaction domain 4B	Homo sapiens	58-62	
21088568-6	2011	SUMMARY: Recognizing hypoisoleucinemia and BCAA antagonism following gastrointestinal bleeding, and its successful treatment by isoleucine infusion has advanced our understanding of the role of BCAA in liver cirrhosis.	Isoleucine	25-35	AT-rich interaction domain 4B	Homo sapiens	194-198	
16501446-1	1997	Branched-chain amino acids (BCAA: leucine, isoleucine and valine) are not just structural constituents of proteins, but have ""pharmacologic"" properties, known for several years: BCAA are catabolized mainly in muscle; can be oxidized with energy production, being nitrogen donors for other amino acids; regulate protein synthesis and degradation; modulate metabolism of neuroactive mediators.	Isoleucine	43-53	AT-rich interaction domain 4B	Homo sapiens	28-32	
16501446-1	1997	Branched-chain amino acids (BCAA: leucine, isoleucine and valine) are not just structural constituents of proteins, but have ""pharmacologic"" properties, known for several years: BCAA are catabolized mainly in muscle; can be oxidized with energy production, being nitrogen donors for other amino acids; regulate protein synthesis and degradation; modulate metabolism of neuroactive mediators.	Isoleucine	43-53	AT-rich interaction domain 4B	Homo sapiens	180-184